Breakthrough medicines. By design.
Breakthrough medicines. By design.
Breakthrough medicines.
By design.
Cambium Bio is a patient-focused, clinical-stage, regenerative medicine company developing a pioneering platform in ophthalmology and tissue regeneration.
Cambium Bio is a patient-focused, clinical-stage, regenerative medicine company developing a pioneering platform in ophthalmology and tissue regeneration.
Cambium Bio is a patient-focused, clinical-stage, regenerative medicine company developing a pioneering platform in ophthalmology and tissue regeneration.
Therapeutic areas
Therapeutic areas
Cambium Bio is advancing novel therapies for:
Cambium Bio is advancing novel therapies for:
Dry Eye Disease (DED)
Dry Eye Disease (DED)
Knee Osteoarthritis
Knee Osteoarthritis
Wound healing
Wound healing
Our Science
Our Science
Cambium Bio's proprietary technology platforms harness the regenerative potential of human platelet lysate and mesenchymal stem cells to develop innovative biologic therapies. Learn more about our science
Cambium Bio's proprietary technology platforms harness the regenerative potential of human platelet lysate and mesenchymal stem cells to develop innovative biologic therapies. Learn more about our science
Our Pipeline
Our Pipeline
Cambium Bio's diversified pipeline includes:
Cambium Bio's diversified pipeline includes:
01.
Elate Ocular®
Elate Ocular®, a late clinical-stage asset for dry eye disease.
02.
Progenza
03.
Sygenus
01.
Elate Ocular®
Elate Ocular®, a late clinical-stage asset for dry eye disease.
02.
Progenza
03.
Sygenus
01.
Elate Ocular®
Elate Ocular®, a late clinical-stage asset for dry eye disease.
02.
Progenza
03.
Sygenus
Stay up to date
Stay up to date
Stay up to date
Sign up for alerts on our latest news, events, and ASX announcements.
Sign up for alerts on our latest news, events, and ASX announcements.
Sign up for alerts on our latest news, events, and ASX announcements.